CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

yahoo_finance
Original article

Cingulate Issued First U.S. Patent for Lead ADHD Asset CTx-1301

Patent ExpiryCTx-1301Positive
AI Analysis

Summary

Cingulate announced the issuance of its first U.S. patent for CTx-1301, its lead ADHD therapeutic asset, strengthening intellectual property protection.

Outcome Details

First U.S. patent issued for CTx-1301

Importance:5/10
Sentiment:
0.60
patentADHDlead assetintellectual property
Related Companies

Read the original article

Published by yahoo_finance on June 16, 2026 12:00 PM

Read Original